Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of neurological disorders
3.2.1.2 Technological advancements in drug delivery systems
3.2.1.3 Aging population and demographic shifts
3.2.1.4 Increasing research and development investments
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory scenario
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter’s analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Product, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Antioxidants
5.3 Apoptosis inhibitors
5.4 Anti-inflammatory agents
5.5 Glutamate antagonists
5.6 Metal ion chelators
5.7 Antidepressants
5.8 Stimulants
5.9 Neurotrophic factors (NTFs)
5.10 Other products
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Intravenous
6.4 Other routes of administration
Chapter 7 Market Estimates and Forecast, By Application, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Neurodegenerative diseases
7.3 Stroke and ischemic injury
7.4 Traumatic brain injury (TBI)
7.5 Depression and bipolar disorders
7.6 Spinal cord injury
7.7 Other applications
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Drug stores
8.5 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 Biogen Inc.
10.3 Dr. Reddy’s Laboratories Ltd.
10.4 Eli Lilly and Company
10.5 GSK plc
10.6 Merck & Co., Inc.
10.7 Novartis AG
10.8 Pfizer Inc.
10.9 Sanofi
10.10 Teva Pharmaceutical Industries Limited
